✦ LIBER ✦

Comparison of immunological responses in node-positive and node-negative breast cancer patients receiving a HER2/neu E75 peptide vaccine

✍ Scribed by M. T. Hueman; J. M. Gurney; C. E. Storrer; L. Kotula; K. Jackson; M. Wilson; C. D. Shriver; S. Ponnian; G. E. Peoples

Book ID: 110547692
Publisher: Springer
Year: 2004
Tongue: English
Weight: 296 KB
Volume: 11
Category: Article
ISSN: 1068-9265
DOI: 10.1007/bf02524030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase IB trial of the Her2/neu peptide (

Phase IB trial of the Her2/neu peptide (E75) vaccine for optimal dosing in node-negative breast cancer patients

✍ E.A. Mittendorf; S. Khoo; Z.A. Dehqanzada; M.T. Hueman; C.E. Storrer; K.A. Harri 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Clinical and Immunologic Responses of HL

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

✍ Ritesh Patil; Guy T. Clifton; Jarrod P. Holmes; Asna Amin; Mark G. Carmichael; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 728 KB

A more sensitive immunological monitorin

A more sensitive immunological monitoring tool for cancer vaccine trials: A direct comparison of HLA-A2 dimer and tetramer molecules in measuring the in vivo immune response to a HER2/neu peptide-based vaccine (E75) in prostate and breast cancer patients

✍ Matthew T. Hueman; Jennifer Gurney; Michael Woll; Catherine Storrer; David McLeo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 53 KB

P32 Prognostic parameters in node negati

P32 Prognostic parameters in node negative breast cancer receiving adjuvant CMF: Analysis of a randomized trial with emphasis on p53 and HER 2 neu

✍ A.C. Hardy-Bessard; A. De Roquancourt; P.H. Cottu; P. De Cremoux; M. Marty; M. E 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Prognostic value of the quantitative mea

Prognostic value of the quantitative measurement of the oncoprotein p185Her-2/neu in a group of patients with breast cancer and positive node involvement

✍ Uriel Bohn; José Aguiar; Cristina Bilbao; Adolfo Murias; Victor Vega; Ricardo Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 109 KB

## Abstract Our study attempts to determine the prognostic value of the quantitative measurement of the oncoprotein p185^Her‐2/neu^ in a group of patients with breast cancer and positive node involvement. In a series of 217 patients with breast cancer and positive nodes in whom the oncoprotein p185

Immunological monitoring of in vitro and

Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/neu MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients

✍ S. Khoo; C.E. Storrer; K.A. Harris; Y.H. Jama; Z.A. Dehqanzada; C.D. Shriver; E. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB